Literature DB >> 23433485

The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.

Danuta S Kalinowski1, Patric J Jansson, Zaklina Kovacevic, Des R Richardson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23433485      PMCID： PMC6837417          DOI： 10.1179/1351000213Y.0000000041

Source DB:  PubMed          Journal:  Redox Rep        ISSN： 1351-0002            Impact factor:   4.412


× No keyword cloud information.
  15 in total

1.  Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.

Authors:  David B Lovejoy; Patric J Jansson; Ulf T Brunk; Jacky Wong; Prem Ponka; Des R Richardson
Journal:  Cancer Res       Date:  2011-07-12       Impact factor: 12.701

2.  Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.

Authors:  Y Yu; Y Suryo Rahmanto; D R Richardson
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.

Authors:  Zaklina Kovacevic; Sherin Chikhani; David B Lovejoy; Des R Richardson
Journal:  Mol Pharmacol       Date:  2011-06-30       Impact factor: 4.436

Review 4.  The evolution of iron chelators for the treatment of iron overload disease and cancer.

Authors:  Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2005-12       Impact factor: 25.468

5.  Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.

Authors:  Paul V Bernhardt; Philip C Sharpe; Mohammad Islam; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

6.  Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.

Authors:  Jun Yuan; David B Lovejoy; Des R Richardson
Journal:  Blood       Date:  2004-05-18       Impact factor: 22.113

7.  The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.

Authors:  Justin H Gundelach; Ajay A Madhavan; Peter J Wettstein; Richard J Bram
Journal:  FASEB J       Date:  2012-11-07       Impact factor: 5.191

8.  N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis.

Authors:  Wen Liu; Fei Xing; Megumi Iiizumi-Gairani; Hiroshi Okuda; Misako Watabe; Sudha K Pai; Puspa R Pandey; Shigeru Hirota; Aya Kobayashi; Yin-Yuan Mo; Koji Fukuda; Yi Li; Kounosuke Watabe
Journal:  EMBO Mol Med       Date:  2012-01-13       Impact factor: 12.137

9.  Optimization of immunoglobulin substitution therapy by a stochastic immune response model.

Authors:  Marc Thilo Figge
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Immune microenvironment in tumor progression: characteristics and challenges for therapy.

Authors:  Valerie Chew; Han Chong Toh; Jean-Pierre Abastado
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375
View more
  1 in total

1.  Increased generation of intracellular reactive oxygen species initiates selective cytotoxicity against the MCF-7 cell line resultant from redox active combination therapy using copper-thiosemicarbazone complexes.

Authors:  Fady N Akladios; Scott D Andrew; Christopher J Parkinson
Journal:  J Biol Inorg Chem       Date:  2016-03-07       Impact factor: 3.358
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.